Yes Joe - but we know they are sitting on data. They have at least 9 qpcrs and multiple pk results as well as tumor antigen data. They are sitting on results as though its a close phII/III model, not open label phI. Personally, I see they're lack of data sharing as a positive. Looks good to the fda and may help their application for orphan status or most rapid accelerated approval pathway. But that is just my opinion and is conjecture...none of us know...because they're not telling.